BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62:1040-1046. [PMID: 25450208 DOI: 10.1016/j.jhep.2014.10.044] [Cited by in Crossref: 97] [Cited by in F6Publishing: 97] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
2 Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Medical Journal of Australia 2016;204:268-72. [DOI: 10.5694/mja16.00106] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
3 Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:21-36. [PMID: 26558305 DOI: 10.1586/17474124.2016.1119042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
4 Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, Svarovskaia E, Knox SJ, Loustaud-Ratti V, Asselah T. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016;64:1049-56. [PMID: 27351341 DOI: 10.1002/hep.28706] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 14.2] [Reference Citation Analysis]
5 Gayam V, Khalid M, Mandal AK, Hussain MR, Mukhtar O, Gill A, Garlapati P, Shrestha B, Guss D, Sherigar J, Mansour M, Mohanty S. Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting. Gastroenterology Res 2018;11:130-7. [PMID: 29707080 DOI: 10.14740/gr999w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
6 Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am. 2015;44:807-824. [PMID: 26600221 DOI: 10.1016/j.gtc.2015.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
7 Abd Alla MDA, Dawood RM, Rashed HAE, Farrag G, Ammar IAE, Mahmoud MMA, Salum GM, Altanbouly AMA, El Meguid MA, Awady MKE. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Arch Virol 2021;166:1071-81. [PMID: 33533976 DOI: 10.1007/s00705-021-04969-4] [Reference Citation Analysis]
8 Sakr AA, Ahmed AE, Abd El-Maksoud MDE, Gamal A, El-Garem H, Ahmed OM. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Infect Genet Evol 2020;86:104606. [PMID: 33127459 DOI: 10.1016/j.meegid.2020.104606] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292. [PMID: 27087015 DOI: 10.1111/apt.13633] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 15.8] [Reference Citation Analysis]
10 Yang S, K R J, Lim S, Choi TG, Kim JH, Akter S, Jang M, Ahn HJ, Kim HY, Windisch MP, Khadka DB, Zhao C, Jin Y, Kang I, Ha J, Oh BC, Kim M, Kim SS, Cho WJ. Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections. J Med Chem 2015;58:9546-61. [PMID: 26613291 DOI: 10.1021/acs.jmedchem.5b01064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
11 Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 2018;15:180. [PMID: 30466446 DOI: 10.1186/s12985-018-1094-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
12 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
13 Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D, Doehle B, Knox SJ, Massetto B, Mchutchison JG, Esmat G. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Journal of Hepatology 2015;63:581-5. [DOI: 10.1016/j.jhep.2015.04.023] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
14 Garagiola E, Ferrario L, Croce D, Menzaghi B, Quirino T, Rizzardini G, Foglia E. HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. Digestive and Liver Disease 2016;48:1200-7. [DOI: 10.1016/j.dld.2016.06.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-80. [PMID: 25089861 DOI: 10.7326/M14-0095] [Cited by in Crossref: 107] [Cited by in F6Publishing: 58] [Article Influence: 13.4] [Reference Citation Analysis]
16 Nagaty A, Abd El-Wahab EW. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One 2017;12:e0184654. [PMID: 28981513 DOI: 10.1371/journal.pone.0184654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
17 Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol 2016;6:119-45. [PMID: 27493460 DOI: 10.1016/j.jceh.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
18 Fathi HM, Abdel Wahed WY, Gomaa AA, Hassan EA, Eid HM, Reheem FA, Senara SH. A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00023-4] [Reference Citation Analysis]
19 Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016;41:478-85. [PMID: 27440554 DOI: 10.1111/jcpt.12426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
20 Mariño Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother 2015;16:1929-43. [PMID: 26219918 DOI: 10.1517/14656566.2015.1070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Khedr MA, Sira AM, Saber MA, Raia GY. Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response? Int J Hepatol 2015;2015:617623. [PMID: 26640716 DOI: 10.1155/2015/617623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zayed RA, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. Viral Immunol. 2017;30:560-567. [PMID: 28731371 DOI: 10.1089/vim.2017.0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
26 Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, Mcphee F, Zhou N, Wind-rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. Journal of Hepatology 2015;62:1204-6. [DOI: 10.1016/j.jhep.2014.12.025] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
27 Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt - past, present, and future. Int J Gen Med 2017;10:1-6. [PMID: 28053553 DOI: 10.2147/IJGM.S119301] [Cited by in Crossref: 72] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
28 Bruno R, Aghemo A. Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? J Hepatol 2015;63:1294. [PMID: 26297328 DOI: 10.1016/j.jhep.2015.05.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-tack K, Murray J, Birnkrant D, Struble K. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens. J Viral Hepat 2018;25:969-75. [DOI: 10.1111/jvh.12896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
30 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
31 Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:25-35. [PMID: 28404108 DOI: 10.1016/S2468-1253(16)30001-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
32 Othumpangat S, Ray SD, Noti JD. Antiviral Drugs. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2016. pp. 261-81. [DOI: 10.1016/bs.seda.2016.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Aboushady M, Alwassief A, Abdelrazik M, Ziada D, Shahba H, Elmestikawy A, Elbahrawy A. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. J Interferon Cytokine Res 2019;39:539-46. [PMID: 31173550 DOI: 10.1089/jir.2019.0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol 2018;68:814-26. [PMID: 29229584 DOI: 10.1016/j.jhep.2017.11.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
35 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
36 Kurniawan J, Gani RA, Hasan I, Sulaiman AS, Lesmana CRA, Jasirwan COM, Kalista KF, Nababan SHH, Zulkifly S. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability. Indian J Gastroenterol 2018;37:520-5. [PMID: 30637537 DOI: 10.1007/s12664-018-0921-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood N. Sofosbuvir and Ribavirin Combination Therapy Response in Various Hepatitis C Virus Genotypes in Peshawar, Khyber Pakhtunkhwa. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.99625] [Reference Citation Analysis]
38 El Kassas M, Elbaz T, Elsharkawy A, Omar H, Esmat G. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018;16:345-350. [PMID: 29506418 DOI: 10.1080/14787210.2018.1448709] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
39 Wehmeyer MH, Jordan S, Lüth S, Hartl J, Stoehr A, Eißing C, Lohse AW, Petersen J, Buggisch P, Schulze Zur Wiesch J. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection. Dig Liver Dis 2015;47:811-4. [PMID: 26091766 DOI: 10.1016/j.dld.2015.05.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Asselah T, Bourlière M. Hepatitis C Virus. Gastroenterology Clinics of North America 2015;44:859-70. [DOI: 10.1016/j.gtc.2015.07.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
41 Kwo PY. Regimens for Cirrhotic Patients. Clin Liver Dis 2015;19:657-67, vi. [PMID: 26466654 DOI: 10.1016/j.cld.2015.06.006] [Reference Citation Analysis]
42 El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, Ezzat S, Tahoon M, Abdelsalam L, Abdelhakam SM, Ali-Eldin Z. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med 2019;10:295-302. [PMID: 34652758 DOI: 10.1007/s41999-019-00167-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015;61:1127-34. [DOI: 10.1093/cid/civ438] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
44 Sharma SA, Feld JJ. Management of HCV in cirrhosis-a rapidly evolving landscape. Curr Gastroenterol Rep 2015;17:443. [PMID: 25896437 DOI: 10.1007/s11894-015-0443-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 Chen TY, Jain MK. Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. AIDS Patient Care STDS 2015;29:329-37. [PMID: 26020726 DOI: 10.1089/apc.2014.0247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
46 El Kassas M, Alboraie M, Elsaeed K, Ahmed Y, El Tahan A, Alhaddad O, Salaheldin M, Kabbash I, El Badry M, Fathy T, El-Serafy M, ElShazly Y, Doss W, Esmat G. Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes. Am J Ther 2018;25:e776-9. [PMID: 30124480 DOI: 10.1097/MJT.0000000000000784] [Reference Citation Analysis]
47 Obed A, Jarrad A, Bashir A, Moog G. Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report. Am J Case Rep 2016;17:357-9. [PMID: 27230979 DOI: 10.12659/ajcr.896810] [Reference Citation Analysis]
48 Abdel-Moneim A, Abood A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients. Clin Exp Hepatol. 2018;4:191-196. [PMID: 30324144 DOI: 10.5114/ceh.2018.78123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
49 Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34. [PMID: 25585348 DOI: 10.1155/2015/692408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
50 Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147 [PMID: 26839638 DOI: 10.4254/wjh.v8.i3.139] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
51 Chan J, Chung RT. Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. Clinical Pharmacology in Drug Development 2017;6:147-63. [DOI: 10.1002/cpdd.338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
52 González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016; 22(4): 1421-1432 [PMID: 26819511 DOI: 10.3748/wjg.v22.i4.1421] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
53 Li Z, Ping Y, Yu Z, Wang M, Yue D, Zhang Z, Li J, Zhang B, Shi X, Zhang Y. Dynamic changes in CD45RA(-)Foxp3(high) regulatory T-cells in chronic hepatitis C patients during antiviral therapy. Int J Infect Dis 2016;45:5-12. [PMID: 26875600 DOI: 10.1016/j.ijid.2016.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Llaneras J, Riveiro-Barciela M, Buti M, Esteban R. Hepatitis C virus genotype 4: Genotype 1's little brother. J Viral Hepat 2017;24:4-12. [PMID: 27905173 DOI: 10.1111/jvh.12620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
55 Ping Y, Song M, Wang M, Li Z, Zhang Y. CDR3 repertoire diversity of CD8+ T lymphocytes in patients with HCV. Cell Immunol 2019;336:34-9. [PMID: 30591202 DOI: 10.1016/j.cellimm.2018.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Deterding K, Höner Zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D, Mix H. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42:889-901. [PMID: 26250762 DOI: 10.1111/apt.13343] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 10.9] [Reference Citation Analysis]
57 Shahin AA, Zayed HS, Said M, Amer SA. Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection. Z Rheumatol 2018;77:621-8. [PMID: 28795238 DOI: 10.1007/s00393-017-0356-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
58 Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016;213:206-15. [PMID: 26170396 DOI: 10.1093/infdis/jiv379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
59 Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol 2016;2016:4385643. [PMID: 27471521 DOI: 10.1155/2016/4385643] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
60 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
61 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. J Viral Hepat 2018;25:1078-88. [PMID: 29624809 DOI: 10.1111/jvh.12906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
62 Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ. ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS One 2015;10:e0144004. [PMID: 26650626 DOI: 10.1371/journal.pone.0144004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
63 Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal Eldeen H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37:534-541. [PMID: 27712017 DOI: 10.1111/liv.13266] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
64 Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic‐burban S. How to optimize hepatitis C virus treatment impact on life years saved in resource‐constrained countries. Hepatology 2015;62:31-9. [DOI: 10.1002/hep.27691] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
65 Elsharkawy A, Eletreby R, Fouad R, Soliman Z, Abdallah M, Negm M, Mohey M, Esmat G. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol Hepatol 2017;11:773-8. [PMID: 28480808 DOI: 10.1080/17474124.2017.1326816] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
66 Ayoub WS, Tran TT. Regimens for the Hepatitis C Treatment-Naive Patient. Clin Liver Dis 2015;19:619-27, v. [PMID: 26466651 DOI: 10.1016/j.cld.2015.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
67 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
68 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
69 Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol 2016; 8(2): 92-106 [PMID: 26807205 DOI: 10.4254/wjh.v8.i2.92] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
70 Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70. [PMID: 26586968 DOI: 10.2147/HMER.S55864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
71 Toshikuni N. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver 2017;11:335-48. [PMID: 27840363 DOI: 10.5009/gnl15458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
72 Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki JP, Ledinghen VD, Zoulim F, Tran A, Metivier S, Zarski JP, Samuel D, Guyader D, Marcellin P, Minello A, Alric L, Thabut D, Chazouilleres O, Riachi G, Bourcier V, Mathurin P, Loustaud-Ratti V, D'Alteroche L, Fouchard-Hubert I, Habersetzer F, Causse X, Geist C, Rosa I, Gournay J, Saillard E, Billaud E, Petrov-Sanchez V, Diallo A, Fontaine H, Carrat F; ANRS/AFEF HEPATHER study group. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol 2017;66:39-47. [PMID: 27622858 DOI: 10.1016/j.jhep.2016.08.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 12.3] [Reference Citation Analysis]
73 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
74 Elsharkawy A, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, Said M, Motawea I, El Demerdash T, Seif S, Gaballah A, El Shazly Y, Makhlouf MAM, Waked I, Abdelaziz AO, Yosry A, El Serafy M, Thursz M, Doss W, Esmat G. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther 2017;45:681-7. [DOI: 10.1111/apt.13923] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
75 Selvapatt N, Habibi MS, Brown A. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. J Med Virol 2015;87:1716-21. [PMID: 25914248 DOI: 10.1002/jmv.24228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
76 Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163:51-56. [PMID: 28983675 DOI: 10.1007/s00705-017-3573-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
77 Wang LS, D'Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844-1855. [PMID: 27097298 DOI: 10.1002/jmv.24554] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
78 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study. Sci Rep 2019;9:13593. [PMID: 31537880 DOI: 10.1038/s41598-019-49973-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
79 Feld JJ. HCV elimination: It will take a village and then some. J Hepatol 2020;72:601-3. [PMID: 32057492 DOI: 10.1016/j.jhep.2020.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 2015;59:6807-15. [PMID: 26282418 DOI: 10.1128/AAC.01229-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
81 Mikolas LA, Jacques K, Huq M, Krasner C, Mambourg SE. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. J Pharm Pract 2019;32:655-63. [PMID: 29783912 DOI: 10.1177/0897190018777345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
82 Majumdar A, Kitson MT, Roberts SK. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. Drugs 2015;75:823-34. [PMID: 25943281 DOI: 10.1007/s40265-015-0401-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
83 Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. J Clin Exp Hepatol 2019;9:4-12. [PMID: 30765933 DOI: 10.1016/j.jceh.2018.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
84 Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. Clin Drug Investig 2017;37:635-46. [PMID: 28409482 DOI: 10.1007/s40261-017-0521-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
85 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
86 Resende C, Pereira T, Ventura F, Brito C. Leg ulcer as a manifestation of eosinophilic vasculitis in a patient with hepatitis C virus infection, medicated with pegylated interferon/ribavirin. BMJ Case Rep 2015;2015:bcr2015209377. [PMID: 26065548 DOI: 10.1136/bcr-2015-209377] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Alian SM, Wahba MO, Gomaa AF, Khalil SS. The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00021-6] [Reference Citation Analysis]
88 El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12:1265-1272. [PMID: 29757684 DOI: 10.1080/17474124.2018.1476137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
89 Waked I. Case study of hepatitis C virus control in Egypt: impact of access program. Antivir Ther 2022;27:13596535211067592. [PMID: 35491550 DOI: 10.1177/13596535211067592] [Reference Citation Analysis]
90 Beinhardt S, Peck-Radosavljevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transpl Int. 2015;28:1011-1024. [PMID: 25864369 DOI: 10.1111/tri.12577] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
91 Hassanien KS, El-Sayed EM, Ismail RS, Zakarya ZM, Helal GK. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. J Clin Pharm Ther 2021;46:942-9. [PMID: 33768560 DOI: 10.1111/jcpt.13417] [Reference Citation Analysis]
92 Fadl N, Salem TZ. Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. Rev Med Virol 2020;30:e2120. [PMID: 32478480 DOI: 10.1002/rmv.2120] [Reference Citation Analysis]
93 Asselah T. Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available. J Hepatol 2015;62:996-9. [PMID: 25747660 DOI: 10.1016/j.jhep.2015.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
94 Yakoot M, Abdo AM, Yousry A, Helmy S. Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy. Drug Des Devel Ther 2016;10:2659-67. [PMID: 27601883 DOI: 10.2147/DDDT.S111496] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
95 Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557 [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
96 Villani R, Monami M, Di Cosimo F, Fioravanti G, Mannucci E, Vendemiale G, Serviddio G. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. J Viral Hepat 2019;26:1249-56. [PMID: 31243849 DOI: 10.1111/jvh.13169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
97 Tierney AR, Huepfel W, Shaukat AP, Lake JR, Boldt M, Wang Q, Hassan MA. Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. J Immigr Minor Health 2019;21:549-54. [PMID: 29802526 DOI: 10.1007/s10903-018-0758-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Nagaty A, Helmy SH, Abd El-Wahab EW. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Trans R Soc Trop Med Hyg 2020;114:200-12. [PMID: 31722032 DOI: 10.1093/trstmh/trz079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Mohamed EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, Ghareeb DA, Ross B. Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients. J Viral Hepat 2022;29:147-55. [PMID: 34773341 DOI: 10.1111/jvh.13630] [Reference Citation Analysis]
100 Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45-53. [PMID: 27275625 DOI: 10.1111/liv.13186] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 20.7] [Reference Citation Analysis]
101 Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. J Hepatol. 2017;. [PMID: 29223371 DOI: 10.1016/j.jhep.2017.11.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
102 Nyalakonda H, Utay NS. A new era of therapy for hepatitis C virus infection: . Current Opinion in Infectious Diseases 2015;28:471-8. [DOI: 10.1097/qco.0000000000000190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]